软组织肉瘤中远处转移与局部晚期疾病的预后差异:EORTC-STBSG数据库研究
该回顾性数据库分析纳入12项EORTC肉瘤试验中2473例接受一线化疗的晚期软组织肉瘤患者,比较仅局部晚期、仅转移及局部晚期合并转移三组的预后。结果显示三组中位总生存分别为15.4、12.9和10.6个月,无进展生存分别为5.8、4.3和3.2个月,差异显著,提示疾病范围应纳入研究设计与日常实践考量。
要点
- 仅局部晚期、仅转移及局部晚期合并转移的晚期STS患者预后存在显著差异。
- 三组中位总生存分别为15.4、12.9和10.6个月,无进展生存分别为5.8、4.3和3.2个月。
- 未来研究设计、结果解读与比较及日常实践应考虑疾病范围分层。
核心结论
- 接受一线化疗的晚期软组织肉瘤患者中,仅局部晚期、仅转移及局部晚期合并转移三组的预后不同。
研究设计与样本
- 回顾性数据库分析,纳入12项EORTC肉瘤试验中2473例接受一线化疗的晚期软组织肉瘤患者。
主要发现
- 仅局部晚期、仅转移及局部晚期合并转移组的中位总生存分别为15.4、12.9和10.6个月,差异显著。
- 三组的中位无进展生存分别为5.8、4.3和3.2个月。
临床怎么用
- 在临床实践、研究设计及结果解读与比较时,应考虑晚期软组织肉瘤患者疾病范围(仅局部晚期、仅转移或两者合并)的预后差异。
局限性
- 本研究为回顾性数据库分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In patients with advanced soft tissue sarcoma (STS) treated with chemotherapy, WHO performance status, histologic subtype and histologic grade are known prognostic factors. Although the difference between the subgroups: locally advanced disease only, metastatic disease only and both local and metastatic disease is easily made, its prognostic relevance is thus far unknown. The aim of this EORTC database study was to study the difference in prognosis between these subgroups in patients receiving first-line chemotherapy for advanced STS. METHODS: A retrospective database analysis was performed on 2473 patients receiving first-line chemotherapy for advanced STS from 12 EORTC sarcoma trials to establish the difference in prognosis for the three subgroups. End-points were overall survival, progression-free survival and overall response rate. Factors studied were age, sex, histologic subtype, histologic grade, WHO performance status, treatment and time since initial diagnosis. RESULTS: Overall survival differed significantly between patients with locally advanced disease only, with metastatic disease only and with both locally advanced and metastatic disease with a median overall survival of 15.4, 12.9 and 10.6 months, respectively. Similar differences were seen for progression-free survival (5.8, 4.3 and 3.2 months, respectively). CONCLUSION: This large retrospective database study shows that patients with advanced STSs treated with first-line chemotherapy with locally advanced disease, metastatic disease and both local and metastatic disease have different outcomes. This should be accounted for in future study design, interpretation and comparison of study results and daily practice.
引用
- Verschoor AJ, Litière S, Marréaud S, et al. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. Eur J Cancer. 2018. PMID: 29574364. doi:10.1016/j.ejca.2018.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。